INTRODUCTION
Renal cell carcinoma (RCC) affects approximately 38,000 patients in the United States every year, with one third of patients presenting with metastatic disease. 1 Metastatic RCC (MRCC) is resistant to classical cytotoxic chemotherapy and hormonal therapy, 2,3 and the benefit of interferon alfa and interleukin-2 is modest. Interferon therapy results in responses in 10% to 20% of patients with a median duration of 3 to 16 months, 4 whereas intravenous interleukin-2 results in generally durable complete responses (CRs) in approximately 6% of patients, and only in good-risk patients. 5 The treatment of MRCC has recently evolved from being predominantly cytokine-based to being grounded in the use of drugs targeting vascular endothelial growth factor and platelet-derived growth factor pathways. 6 Various antiangiogenic drugs have been studied for the treatment of patients with RCC and have been shown to improve survival. 7 Targeted therapies using sorafenib and sunitinib have recently been approved for use as orally administered agents for the treatment of MRCC. Sunitinib is reserved for the treatment of cytokine-naïve patients, 8 whereas sorafenib was approved for patients with disease that is refractory to cytokine therapy. 9 However, in clinical practice, sunitinib and sorafenib are often both used as first-line and secondline treatments for MRCC. When one agent fails to produce a response in patients, the other agent is often used, resulting in sequential therapy.
Although sorafenib and sunitinib are multitarget tyrosine kinase inhibitors (TKIs), they have distinct affinities for target kinases and distinct pharmacokinetics that could explain a non-crossresistance between the two drugs. 10 Scientific data supporting this sequence are limited and only
11-13 To date, no prospective trials have been published. Therefore we initiated a phase II study of sorafenib to assess its activity and safety in sunitinib-refractory MRCC.
PATIENTS AND METHODS

Patient Selection
All patients were adults with histologically confirmed RCC that was metastatic and measurable according to the Response Evaluation Criteria in Solid Tumors.
14 Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) Յ 2; previous sunitinib therapy as first-line treatment; progression of disease after sunitinib; absolute neutrophil count Ն 1,500/L; hemoglobin Ն 9 g/dL; platelets Ն 100,000/L, normal renal, cardiac, and liver functions; and controlled blood pressure. Patients with all subtypes of RCC were eligible. Patients who had received two previous lines of therapy and with brain metastases were excluded from the study. All patients gave informed consent for their treatment. The study complied with the provisions of the Declaration of Helsinki, Good Clinical Practice Guidelines, and local laws.
Study Design
The study was an open-label, nonrandomized, non-companysponsored, Italian multicenter, phase II study approved by the institutional review boards at eight participating centers. The primary end point was response rate; secondary end points were safety, time to progression (TTP), and overall survival (OS).
Treatment consisted of 8-week cycles of sorafenib (Nexavar, Bayer, Milan, Italy) 400 mg orally twice a day on a continuous basis, and the patients were evaluated for tumor response at the end of week 8. In case of an objective response or stable disease (SD), the patients could receive additional cycles until occurrence of disease progression. Patients were seen on weeks 1, 4, and 8 of each cycle; blood tests to check renal and hepatic functions and blood counts were performed on patients every 2 weeks. All patients had their blood pressure measured at baseline and were required to control it every week. Left ventricular ejection fraction was evaluated with cardiovascular ultrasound at baseline and after each cycle of sorafenib.
Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0). 15 Grade 2 nonhematologic toxicities were managed by holding the drug until resolution to Յ grade 1 and then resuming without a dose reduction. If the patient experienced a second grade 2 nonhematologic toxicity, the drug was reduced by 25%. Grade 3 or 4 hematologic and nonhematologic toxicities were managed through dose interruption, followed by 50% dose reduction. Treatment was discontinued if a grade 3 or 4 toxicity did not resolve within 3 weeks or if a second dose reduction was required.
Assessment of Tumor Response
Tumor measurements were obtained by computed tomography scan, including the brain, before treatment and at the end of week 8 of each cycle. Response and progression were assessed by the treating physicians, who performed their evaluations on the basis of Response Evaluation Criteria in Solid Tumors.
14
Statistical Design
Sample size was established by use of a two-stage minimax Simon's design to evaluate the null hypothesis that the true response was 5% and the alternative hypothesis that the objective response was 15%, with a type I error (␣) of 0.05 and a type II error (␤) of 0.2. Thirty patients were to be treated in the first stage. If at least two responses were observed in the first stage, 22 additional patients were to be entered onto the second stage.
Response rate (CR plus partial response [PR] ) is reported with its exact 95% CI. Toxicities are tabulated by type and grade. TTP was defined as the time from registration until disease progression. OS was calculated from the date of registration to the date of death for any reason. Analyses were carried out on an intent-to-treat population, including all patients without major violations of the eligibility criteria.
RESULTS
Patient Characteristics
Between January 2006 and September 2008, 52 patients (35 men, 17 women; median age, 60 years, range 40 to 78 years) with MRCC were entered onto this phase II trial (Fig 1) . Forty-eight patients (92.3%) had an ECOG PS of 0 to 1, whereas four patients (7.7%) had a ECOG PS of 2. The majority of patients had clear-cell histologic subtypes (86.5%), and the most common site of metastases was the lung (73%). Using the Memorial Sloan-Kettering Cancer Center criteria, the majority of patients fell into the favorable-risk (76.9%) or intermediate-risk (17.3%) groups. Twenty-four (46.2%), 18 (34.6%), and 10 patients (19.2%) had one, two, or more sites of metastasis ( Table 1) .
All patients had received prior sunitinib therapy (schedule "4/2" with a starting dose of 50 mg/d for 4 weeks, followed by a 2 week off-drug period) and had experienced progression during treatment or within 60 days of completing sunitinib. The median duration of prior sunitinib was four cycles; one (1.9%) and 21 patients (40.4%) experienced CR and PR to sunitinib, respectively. Sunitinib-dose reduction of 25% (37.5 mg) and 50% (25 mg) for grade 3 to 4 hematologic and nonhematologic toxicities was observed in 10 (19%) and five patients (9.6%), respectively. Median time between interruption of sunitinib and start of sorafenib was 4 weeks (range, 3 to 8 weeks).
Therapy Administration
At total of 109 cycles were administered. The mean number of cycles per patient was 2.17 (median, two cycles; range, one to 10 cycles). The schedule resulted in a mean received dose-intensity of 668.8 mg/d, or 83.6% of the planned dose-intensity. A dose reduction of 25% (600 mg/d) and 50% (400 mg/d) was adopted in 36 (33%) and 18 cycles (16.5%), respectively, as a result of grade 2 to 4 nonhematologic and hematologic toxicity. Treatment was delayed in eight cycles (7.3%). Reasons for delay were patient's request (five cycles), grade 1
Assessed for eligibility (n = 57)
Follow-up (n = 52) Discontinued the treatment before completing 1 cycle for refusal (n = 2) Discontinued the treatment after 1 cycle for PD (n = 10) Discontinued the treatment after 2 cycles for PD (n = 29) Discontinued after 3 cycles (n = 6) Responders treated until 9 cycles (n = 2) Responders treated until 10 cycles (n = 3)
Refused to participate (n = 1)
Allocated to sorafenib (n = 52) nonhematologic toxicity (two cycles), and investigator's decision (one cycle).
Response and Survival
All patients receiving at least one dose of sorafenib were included in analyses. Table 2 shows responses and survival rates in 52 patients. Two patients did not complete the first cycle (because of refusal to continue the treatment after 3 and 4 weeks, respectively). After one cycle, 40 and 12 patients showed SD and progressive disease (PD), respectively, whereas five cases of PR occurred after two cycles, for an overall response rate of 9.6% (95% CI, 5% to 17%). A total of 76.9% of patients had SD for at least one cycle (8 weeks), and 80.8% had PD after two cycles (16 weeks). Thirteen patients (25%) had some tumor reduction in target lesions (a reduction of 50%, 40%, 20%, and 10% in three, two, five, and three patients, respectively).
Median follow-up was 8 months (range, four to 16 months). Median TTP and median OS were 16 weeks (range, 8 to 40 weeks) and 32 weeks (range, 16 to 64 weeks), respectively (Table 3) . Median survival in responders was 48 weeks (range, 44 to 64 weeks).
Note that two PRs were observed among sunitinib responders, whereas two responses were noted in patients with previous SD with sunitinib, and one response was noted in a nonresponder to sunitinib (Table 3 ).
All PRs were in patients with clear-cell subtypes, and the most common site of response was the lung (Table 4) . The five responder patients were treated for nine (three patients) and 10 cycles (two patients), respectively. Two patients achieving response received everolimus as third-line treatment. 
Toxicity
In general, treatment was well tolerated. No toxic deaths occurred. Grade 1 to 2 fatigue, diarrhea, nausea/vomiting, rash, and neutropenia were the most common side effects, noted in 16 (30.8%), 19 (36.5%), 20 (38.5%), 19 (36.5%), and 20 patients (38.5%), respectively. Grade 1 to 2 hand-foot reaction was observed in nine patients (17.3%).
The most important grade 3 hematologic toxicity was neutropenia in five patients (9.6%), whereas the most common grade 3 nonhematologic toxicities were diarrhea in six patients (11.5%), nausea/vomiting in five patients (9.6%), and hypertension in five patients (9.6%).
The five cases of grade 3 hypertension were noted after two cycles and were already reported with previous sunitinib treatment; in fact, during previous therapy, there were five cases of grade 3 hypertension requiring appropriate antihypertensive drugs. During sorafenib, these patients needed to add an angiotensin-converting enzyme inhibitor to previous drugs.
Grade 4 hematologic toxicity was limited to neutropenia in three patients and to nausea, anemia, and hand-foot reaction in one patient each. All grade 4 toxicity resolved with appropriate therapy (Table 5) .
DISCUSSION
To our knowledge, this study represents the first prospective investigation of sequential sorafenib in sunitinib-refractory MRCC. Prior retrospective studies suggested activity and tolerability with this agent in second-line treatment, but those reports are subject to several biases.
11-13
Despite the absence of prospective information, in clinical practice, sequential therapy with sorafenib and sunitinib has become de facto a standard treatment. A prospective study to evaluate the efficacy and safety of sorafenib after sunitinib exposure is necessary to better define the clinical benefit of this algorithm.
The scientific rationale of our trial was that although sorafenib and sunitinib are multitargeted TKIs, they have similar, but not identical, targets and a substantial variety of binding specificity among drugs targeting the same kinases.
10,16
Although sunitinib is an inhibitor of c-kit, platelet-derived growth factor receptor ␣ and ␤, vascular endothelial growth factor receptors (VEGFRs), and FLT-3, sorafenib is a potent raf kinase inhibitor and targets VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor ␤.
Resistance to single-agent antiangiogenic therapy may develop by way of compensatory mechanisms that are driven by upregulation of vascular endothelial growth factor, fibroblast growth factors, and activation of angiogenesis by interleukin-8, RAS, or PI3K/Akt, which could activate or be activated by hypoxia-inducible factor ␣.
17
Sorafenib, targeting RAF, could directly block the overexpressed VEGF pathway and indirectly block PI3K/akt and other pathways, such as apoptosis. 18 In the present study, we hypothesized that drug resistance that emerged after sunitinib would be overcome by sorafenib, which could block iperexpressed kinases and apoptosis.
Our study shows that sorafenib was well tolerated and demonstrated a similar response rate compared with that of previous trials with sorafenib in cytokine-refractory patients; however, it was less active than we expected, according our statistical design. Toxicity from treatment with sorafenib in our study was consistent with that of previous trials. 9 Grade 4 toxicity was rare and well managed with supportive care, and grade 2 to 3 toxicity was well controlled with dose modification. Fatigue, diarrhea, nausea/vomiting, and rash were higher compared with that of the study by Escudier et al, 9 but it is important to note that our patients were pretreated with another TKI with a similar toxicity profile.
Grade 3 hypertension was higher, but the number of patients who reported hypertension was related to previous treatment; in fact, all five cases of grade 3 hypertension appeared during previous sunitinib therapy. Hypertension has been noted with TKI and was expected with this class of drug.
19 Grade 3 hypertension was easily managed with antihypertensive drugs and resolved on discontinuation of the study treatment.
The study has several limitations. First, it is important to note that the responses in this study were investigator-assessed, and because independent review of scans can result in lowering of the response rate relative to the investigator-assessed response, such an effect should be taken into consideration when interpreting the results. Another limitation is that this was a single-agent, nonrandomized study without a control arm, with limitations in determining the benefit of other agents such as bevacizumab alone or in combination with cytokines, adding two agents together, or treatment with an agent that targets different pathways (eg, everolimus or temsirolimus). It is important to note that at the start of our trial, we did not possess the selection of drugs and wealth of information we do today. Besides, the efficacy of targeted agents is better evaluated with other end points, such as tumor shrinkage, TTP, progression-free survival, and OS, than only the response rate.
Also, our statistical design could be subject to criticism. We have hypothesized a minimal response of 5%, with a 15% response required for a positive trial. At the time of protocol writing, only the results of phase III showed a 10% response to sorafenib after cytokine treatment.
9 Considering that the populations were different, with different studies (phase III v phase II) and different end points, speculating on an overexpression of potential targets for sorafenib after sunitinib, we have hypothesized a higher response rate than the previous phase III studies. Often the response rate in phase II studies is higher than that of phase III studies. Surely today, with much more literature examining sorafenib, we would use a different statistical design and different end points.
The development of several targeted agents means the physician is now faced with the dilemma of which agent to give, and in which order, to provide optimal benefit. Tamaskar et al 20 reported a response rate of 20% in patients receiving sorafenib or sunitinib after therapy with a variety of antiangiogenic agents. Axitinib has demonstrated promising activity in cytokine-refractory MRCC, with a response rate of 44.2% and a median TTP of 15.7 months. 21 Rini et al 22 have reported a response rate to sunitinib of 23% in patients with disease that has become refractory to bevacizumab.
A single-arm phase II study does not allow for direct comparison of sorafenib with sunitinib and axitinib. However, the reported response rate, tumor shrinkage, TTP, and OS demonstrate that sorafenib might be a less promising drug in pretreated MRCC, although a randomized controlled trial is needed to confirm this finding. Methodologic differences between trials, including trial design and patient eligibility, probably account for some differences in the results. For example, our patients received sunitinib as first-line treatment, which, to date, gives the best results in terms of OS. Prospective randomized trials will be required to provide insight into the most effective option after disease progression with a target agent.
Our data are consistent with the hypothesis that drug resistance emerging after initial use of sunitinib is not completely overcome by sorafenib, and options for overcoming resistance to antiangiogenic therapy may include novel strategies, such as blocking the mammalian target of rapamycin (mTOR). This strategy has been tested in a clinical trial with everolimus, an mTOR inhibitor that has been shown to have a progression-free survival advantage when used in patients who had experienced disease progression on prior TKI therapy. 23 In this study, everolimus was compared with placebo, although it could be useful to compare an mTOR inhibitor with another targeted agent. This strategy is now being tested in clinical trials evaluating the efficacy of temsirolimus with sorafenib as second-line therapy in patients who have experienced treatment failure with first-line sunitinib (NCT00474786) or temsirolimus in combination with bevacizumab after TKI failure (NCT00782275). 24 Considering the multiple options for treatment of MRCC, it is important to identify the correct sequence to improve the survival of our patients.
Our results show that sorafenib has manageable toxic effects and limited efficacy in sunitinib-refractory MRCC. Further clinical trials, specially comparing a TKI with an mTOR inhibitor, will define the best second-line treatment for patients who experience treatment failure with first-line sunitinib.
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